A healthy tension in translational research

J Clin Invest. 2014 Apr;124(4):1425-9. doi: 10.1172/JCI75840. Epub 2014 Apr 1.

Abstract

I would like to express my sincere appreciation to the American Society for Clinical Investigation and the Harrington Discovery Institute for the honor of being named the inaugural recipient of the Harrington Prize for Innovation in Medicine. I accept this distinction with a deep sense of gratitude and debt to my mentors, trainees, colleagues, collaborators, patients, and family. Moments of recognition such as this are rare, savored, and sustaining. They also invariably provoke personal reflection about what exactly is being recognized. If something innovative truly stands apart in my work, I have come to the conclusion that it relates less to the methods utilized to address questions and more to the questions I choose to ask, and when I ask them.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / physiology
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Animals
  • Awards and Prizes
  • Fibrillins
  • Humans
  • Loeys-Dietz Syndrome / etiology
  • Loeys-Dietz Syndrome / genetics
  • Marfan Syndrome / drug therapy
  • Marfan Syndrome / etiology
  • Marfan Syndrome / genetics
  • Mice
  • Microfilament Proteins / genetics
  • Microfilament Proteins / physiology
  • Scleroderma, Systemic / etiology
  • Scleroderma, Systemic / genetics
  • Signal Transduction
  • Societies, Medical
  • Transforming Growth Factor beta / physiology
  • Translational Research, Biomedical*
  • United States

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Fibrillins
  • Microfilament Proteins
  • Transforming Growth Factor beta
  • Angiotensin II